Bispecific T-cell engager: Difference between revisions

Latest revision as of 23:16, 25 March 2024

Recombinant proteins that bind to two different antigens, one of which activates T cells and the other binds a cancer target
Used in treating some hematologic malignancies

Some of the most serious adverse effects include cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome
- Usually within days of first dose
Causes hypogammaglobulinemia that can last months to years
Most patients develop some neutropenia, which can last weeks
Infections are common, mostly bacterial and viral and occasionally fungal
- Bacterial pneumonia is most common
- COVID-19, with prolonged course
- EBV and CMV, cases of JCV

@@ Line 1: / Line 1: @@
+== Background ==
 * Recombinant proteins that bind to two different antigens, one of which activates T cells and the other binds a cancer target
 * Used in treating some hematologic malignancies
+== Safety ==
+=== Adverse Effects ===
+* Some of the most serious adverse effects include [[cytokine release syndrome]] and [[immune effector cell-associated neurotoxicity syndrome]]
+** Usually within days of first dose
+* Causes [[hypogammaglobulinemia]] that can last months to years
+* Most patients develop some [[neutropenia]], which can last weeks
+* Infections are common, mostly bacterial and viral and occasionally fungal
+** Bacterial pneumonia is most common
+** COVID-19, with prolonged course
+** EBV and CMV, cases of JCV
+=== Screening ===
+* Consider baseline HIV, EBV, CMV, hepatitis B, and hepatitis C serologies
+=== Antimicrobial Prophylaxis ===
+* Unclear role for antibiotics and antifungals, in general
+* Likely [[PJP]] and [[VZV]] prophylaxis for duration of treatment
 [[Category:Oncology]]